Aytu BioPharma, Inc. (AYTU)
NASDAQ: AYTU · Real-Time Price · USD
2.390
-0.010 (-0.44%)
Aug 12, 2026, 12:42 PM EDT - Market open
Aytu BioPharma Balance Sheet
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 26.72 | 30.95 | 20.01 | 22.99 | 19.36 | 49.65 |
Cash & Short-Term Investments | 26.72 | 30.95 | 20.01 | 22.99 | 19.36 | 49.65 |
Cash Growth | 47.00% | 54.71% | -12.96% | 18.72% | -61.01% | 3.26% |
Accounts Receivable | 24.49 | 31.16 | 23.53 | 28.94 | 21.71 | 28.18 |
Inventory | 7.46 | 11.43 | 12.14 | 12 | 10.85 | 16.34 |
Other Current Assets | 8.66 | 5.64 | 6.22 | 7.16 | 8.01 | 11.07 |
Total Current Assets | 67.33 | 79.18 | 61.89 | 71.08 | 59.93 | 105.23 |
Net Property, Plant & Equipment | 1.32 | 1.59 | 1.52 | 3.87 | 6.3 | 8.7 |
Other Intangible Assets | 42.49 | 42.2 | 52.45 | 58.97 | 70.63 | 85.46 |
Goodwill | - | - | - | - | - | 65.8 |
Other Long-Term Assets | 0.56 | 1.2 | 2.23 | 2.55 | 0.77 | 0.47 |
Total Assets | 111.69 | 124.18 | 118.1 | 136.46 | 137.62 | 265.67 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accounts Payable | 13.21 | 10.6 | 10.31 | 13.48 | 10.99 | 19.26 |
Accrued Expenses | 34.27 | 38.16 | 38.14 | 46.8 | 44.19 | 57.23 |
Short-Term Debt | 10.41 | 9.06 | 2.4 | 1.56 | 3.81 | 7.93 |
Current Portion of Long-Term Debt | 1.86 | 1.86 | 1.86 | 0.09 | 0.1 | 16.67 |
Other Current Liabilities | 0.22 | 3.38 | 9.52 | 7.09 | 5.36 | 8.35 |
Total Current Liabilities | 59.97 | 63.06 | 62.23 | 69.02 | 64.44 | 109.44 |
Long-Term Debt | 9.55 | 10.9 | 10.88 | 14.71 | 14.28 | 0.18 |
Other Long-Term Liabilities | 7.03 | 31.25 | 17.27 | 13.38 | 14.59 | 18.48 |
Total Long-Term Liabilities | 16.57 | 42.15 | 28.15 | 28.09 | 28.87 | 18.66 |
Total Liabilities | 76.55 | 105.21 | 90.38 | 97.11 | 93.32 | 128.1 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-in Capital | 382.91 | 352.5 | 347.69 | 343.49 | 331.39 | 315.86 |
Retained Earnings | -347.77 | -333.54 | -319.97 | -304.13 | -287.08 | -178.3 |
Shareholders' Equity | 35.14 | 18.97 | 27.72 | 39.36 | 44.31 | 137.57 |
Total Liabilities & Equity | 111.69 | 124.18 | 118.1 | 136.46 | 137.62 | 265.67 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Total Debt | 21.82 | 21.82 | 15.13 | 16.36 | 18.19 | 24.78 |
Net Cash (Debt) | 4.9 | 9.14 | 4.88 | 6.62 | 1.17 | 24.87 |
Net Cash Growth | - | 87.35% | -26.37% | 465.19% | -95.29% | -46.03% |
Net Cash Per Share | 0.42 | 1.46 | 0.88 | 1.98 | 0.80 | 29.70 |
Book Value | 35.14 | 18.97 | 27.72 | 39.36 | 44.31 | 137.57 |
Book Value Per Share | 3.00 | 3.02 | 5.00 | 11.78 | 30.14 | 164.29 |
Tangible Book Value | -7.35 | -23.24 | -24.74 | -19.61 | -26.32 | -13.7 |
Tangible Book Value Per Share | -0.63 | -3.70 | -4.47 | -5.87 | -17.91 | -16.36 |